Group 1 - The core point of the article is that Hendi Pharmaceutical plans to increase its share capital by issuing 4.5 additional shares for every 10 shares held by shareholders, without arranging for cash dividends [1] - As of August 19, 2025, Hendi Pharmaceutical's stock price is 18.80 yuan, reflecting a 0.43% increase from the previous trading day, with a trading volume of 113 million yuan [1] - For the first half of 2025, the company reported revenue of 235 million yuan and a net profit attributable to shareholders of 18.55 million yuan [1] Group 2 - Hendi Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of APIs and formulations, with products in the fields of antipyretic analgesics and anti-infectives [1] - On the same day, the net inflow of main funds was 9.0143 million yuan, accounting for 0.17% of the circulating market value, while the net outflow over the past five days was 15.5961 million yuan, representing 0.29% of the circulating market value [1]

Group 1 - The stock price of Fengyuan Pharmaceutical closed at 7.50 yuan on July 29, 2025, down 1.45% from the previous trading day, with a trading range of 8.94% [1] - The company is primarily engaged in the research, production, and sales of chemical raw materials and formulations, covering various therapeutic areas including antipyretic analgesics, antibiotics, and vitamins [1] - As a key enterprise in the pharmaceutical industry of Anhui Province, Fengyuan Pharmaceutical's business involves multiple segments including raw materials, formulations, and pharmaceutical commerce [1] Group 2 - On July 29, the stock experienced significant volatility, with a drop of over 2% within 5 minutes around 9:35 AM, followed by a rebound of over 2% shortly after at 9:41 AM, indicating active market trading [1] - The net outflow of main funds was 21.79 million yuan, accounting for 0.64% of the circulating market value, suggesting a certain degree of capital withdrawal [1]